TY - JOUR
T1 - Current Status of Multiple Drug Molecules, and Vaccines
T2 - An Update in SARS-CoV-2 Therapeutics
AU - Kandimalla, Ramesh
AU - John, Albin
AU - Abburi, Chandrika
AU - Vallamkondu, Jayalakshmi
AU - Reddy, P. Hemachandra
N1 - Funding Information:
Authors thank DBT for awarding Ramalingaswami Re-entry Fellowship to RK. Authors also thank NIH for supporting PHR with the following grants: R01AG042178, R01AG47812, R01NS105473, and AG060767.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to “flatten” the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. [Figure not available: see fulltext.]
AB - The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to “flatten” the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. [Figure not available: see fulltext.]
KW - HCQ
KW - Protease inhibitor
KW - Remdesivir
KW - SARS-CoV-2
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85087983896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087983896&partnerID=8YFLogxK
U2 - 10.1007/s12035-020-02022-0
DO - 10.1007/s12035-020-02022-0
M3 - Review article
AN - SCOPUS:85087983896
SN - 0893-7648
VL - 57
SP - 4106
EP - 4116
JO - Molecular Neurobiology
JF - Molecular Neurobiology
IS - 10
ER -